SCHEMBL1553772

SCHEMBL1553772

CN(C)/C=C(\C(=O)c1cccs1)c1ccc(Cl)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.56
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
NAPRT Q6XQN6 1/20 0.40
ALDH1A1 P00352 4/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 8/20 0.39
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 6/20 0.37
KMT2A Q03164 3/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
LTC4S Q16873 1/20 0.36
S1PR4 O95977 1/20 0.36
HPGD P15428 1/20 0.36
S1PR1 P21453 1/20 0.36
NTSR1 P30989 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12709027 1.00 TDP1 (0.56) TDP1CYP11B1CYP11B2CES2CES1
SCHEMBL1553773 1.00 TDP1 (0.56) TDP1CYP11B1CYP11B2CES2CES1
SCHEMBL1553299 0.81 CYP11B1 (0.50) CYP11B1CYP11B2CES2CES1NAPRT
SCHEMBL1553298 0.81 CYP11B1 (0.50) CYP11B1CYP11B2CES2CES1NAPRT
SCHEMBL12709046 0.81 CYP11B1 (0.50) CYP11B1CYP11B2CES2CES1NAPRT
SCHEMBL2975090 0.79 HPGDS (0.51) CES2CES1ALDH1A1LMNARAB9A
SCHEMBL2975094 0.79 HPGDS (0.51) CES2CES1ALDH1A1LMNARAB9A
SCHEMBL23832211 0.77 NAPRT (0.54) TDP1CYP11B1CYP11B2NAPRTALDH1A1
SCHEMBL12708959 0.76 CACNA1B (0.44) CYP11B1CYP11B2CES2CES1NAPRT
SCHEMBL1554028 0.76 CACNA1B (0.44) CYP11B1CYP11B2CES2CES1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1439175-B1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2011-04-27 EP disclosed
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1439175-A1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF CBR3, AHR, HCCS TDP1 1988/4885CYP11B1 110/4885CYP11B2 109/4885
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof ADORA2B, ADORA2A, ADORA3 TDP1 3907/4885CYP11B1 209/4885CYP11B2 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.